Square Pharmaceuticals PlcDSEBD: SQURPHARMA

SQURPHARMA: Strong revenue and profit growth, with higher EPS and robust operating cash flow

· Issued by Square Pharmaceuticals Plc

Consolidated revenue and profit rose strongly year-over-year, with EPS and NOCFPS showing robust growth. Investments in assets and higher dividend payouts marked the period, while management highlighted continued business momentum and no significant post-period events.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Square Pharmaceuticals

All Square Pharmaceuticals news releases